Skip to main content
. 2023 Jun 12;39(5):332–346. doi: 10.1089/jop.2022.0184

FIG. 2.

FIG. 2.

Mean plasma concentration versus time profiles of QLS-101 and levcromakalim in Beagle dogs. (A) Plasma concentrations of QLS-101 following once-daily topical ocular administration of 3 concentrations of QLS-101 for 28 consecutive days. (B) Plasma concentrations of levcromakalim following once-daily topical ocular administration of 3 concentrations of QLS-101 for 28 consecutive days. Presence of levcromakalim in plasma confirms conversation of QLS-101 to levcromakalim. Solid lines represent day 1 and dashed lines represent day 28 data.